For the quarter ended March 2025, Revvity (RVTY) reported revenue of $664.76 million, up 2.3% over the same period last year. EPS came in at $1.01, compared to $0.98 in the year-ago quarter.
The reported revenue represents a surprise of +0.39% over the Zacks Consensus Estimate of $662.17 million. With the consensus EPS estimate being $0.96, the EPS surprise was +5.21%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Revvity performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Organic revenue growth - Life Sciences: 2% compared to the 6.1% average estimate based on three analysts.
- Organic revenue growth - Total: 4% versus 3.6% estimated by three analysts on average.
- Organic revenue growth - Diagnostics: 5% compared to the 1.5% average estimate based on three analysts.
- Net Sales- Life Sciences: $340.40 million versus the three-analyst average estimate of $338.13 million. The reported number represents a year-over-year change of +12.3%.
- Net Sales- Diagnostics: $324.37 million compared to the $324.78 million average estimate based on three analysts. The reported number represents a change of -6.6% year over year.
View all Key Company Metrics for Revvity here>>>
Shares of Revvity have returned -10.7% over the past month versus the Zacks S&P 500 composite's -4.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Revvity Inc. (RVTY): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
